Table 1 Characteristics of the study patients according to treatment arm
Characteristics | Carboplatin-pemetrexed-atezolizumab (n = 76) | Carboplatin-pemetrexed-atezolizumab-bevacizumab (n = 73) |
|---|---|---|
Median age (range), years | 66.5 (38–82) | 67 (38–83) |
Sex, n (%) | ||
Male | 53 (69.7%) | 50 (68.5%) |
Female | 23 (30.3%) | 23 (31.5%) |
Smoking status, n (%) | ||
Never | 18 (23.7%) | 17 (23.3%) |
Former or current | 58 (76.3%) | 56 (76.7%) |
EGFR mutation status, n (%) | ||
Negative | 58 (76.3%) | 56 (76.7%) |
Exon 19 deletion | 9 (11.9%) | 8 (11.0%) |
L858R | 7 (9.2%) | 8 (11.0%) |
Other mutations | 2 (2.6%) | 1 (1.3%) |
PD-L1 TPS, n (%) | ||
<1% | 27 (35.5%) | 27 (37.0%) |
1–49% | 22 (29.0%) | 19 (26.0%) |
≥50% | 15 (19.7%) | 10 (13.7%) |
Unknown | 12 (15.8%) | 17 (23.3%) |
Metastases, n (%) | ||
Liver | 5 (6.6%) | 5 (6.8%) |
Brain | 11 (14.5%) | 11 (15.1%) |
Pleural effusion | 20 (26.3%) | 18 (24.7%) |
